MGMT and glioblastoma: Tumor Treating Fields (TTFields), which disrupt cell division with alternating electric fields, are initiated 4–7 weeks post-radiotherapy during maintenance TMZ in selected patients (supratentorial GBM; KPS ≥60), improving mOS to 31.6 months in MGMT-methylated patients and 20.9 months overall (EF-14 trial), with minimal toxicity (mainly skin irritation), and are endorsed by National Comprehensive Cancer Network (NCCN) and American Society for Radiation Oncology (ASTRO) 2025 guidelines (Table 1) [12,16,17].